SCHEMBL31248840

SCHEMBL31248840

COC(=O)CN(C)C(=O)CCC(=O)C(C)C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 4/20 0.37
CA12 O43570 2/20 0.33
CA9 Q16790 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
MLYCD O95822 1/20 0.31
HSD17B10 Q99714 1/20 0.30
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30
CA7 P43166 1/20 0.30
CA14 Q9ULX7 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9915044 0.77 TSHR (0.42) MEN1KMT2ATSHRCA12CA9
SCHEMBL17629535 0.76 CA12 (0.50) MEN1KMT2ATSHRCA12CA9
SCHEMBL8279035 0.76 TSHR (0.65) MEN1KMT2ATSHRCA12CA9
SCHEMBL23135461 0.76 TSHR (0.41) MEN1KMT2ATSHRCA12CA9
SCHEMBL4589551 0.76 TSHR (0.43) MEN1KMT2ATSHRCA12CA9
SCHEMBL17208358 0.75 MLYCD (0.41) MEN1KMT2ATSHRCA12CA9
SCHEMBL26700537 0.73 MEN1 (0.35) MEN1KMT2ACA12CA9CA1
SCHEMBL31591165 0.73 KDM5A (0.54) TSHRCA12CA9CA2CA7
SCHEMBL10165864 0.72 CHRNB2 (0.48) HSD17B10
SCHEMBL31307036 0.71 KDM5A (0.55) CA12CA9CA2CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720057-A2 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2026-04-08 EP disclosed
WO-2024249888-A2 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2024-12-05 WO disclosed